{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:52:34Z","timestamp":1790376754383,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jcf.2021.07.018","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T23:44:44Z","timestamp":1629935084000},"page":"212-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR"],"prefix":"10.1016","volume":"21","author":[{"given":"David","family":"Drummond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-4128","authenticated-orcid":false,"given":"J\u00e9r\u00e9my","family":"Dana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureline","family":"Berteloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena K.","family":"Schneider-Futschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Chedevergne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bailly-Botuha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Nguyen-Khoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Cornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0345-963X","authenticated-orcid":false,"given":"Dominique","family":"Debray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Sermet-Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2021.07.018_bib0001","unstructured":"European Cystic Fibrosis Society. ECFS Patient Registry; Annual Data Report 2019."},{"key":"10.1016\/j.jcf.2021.07.018_bib0002","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2021.07.018_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra043184","article-title":"Cystic Fibrosis","author":"Rowe","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2021.07.018_bib0004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2021.07.018_bib0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2021.07.018_bib0006","article-title":"Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis","author":"Burgel","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2021.07.018_bib0007","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcf.2018.12.011","article-title":"Predictive factors for lumacaftor\/ivacaftor clinical response","volume":"18","author":"Masson","year":"2019","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2021.07.018_bib0008","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/MOG.0000000000000624","article-title":"Hepatic manifestations of cystic fibrosis","volume":"36","author":"Dana","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jcf.2021.07.018_bib0009","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients","volume":"69","author":"Bo\u00eblle","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2021.07.018_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOG.0000000000000508","article-title":"Modifier genes in cystic fibrosis-related liver disease","volume":"35","author":"Debray","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jcf.2021.07.018_bib0011","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jcf.2020.05.002","article-title":"A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease","volume":"19","author":"Karnsakul","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.07.018_bib0012","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MPG.0000000000000758","article-title":"Increase of Serum \u03b3-Glutamyltransferase Associated With Development of Cirrhotic Cystic Fibrosis Liver Disease","volume":"61","author":"Bodewes","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2021.07.018_bib0013","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v11.i12.761","article-title":"Lumacaftor\/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients","volume":"11","author":"Kutney","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jcf.2021.07.018_bib0014","article-title":"Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study","author":"Colombo","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2021.07.018_bib0015","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/hep.28016","article-title":"Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease","volume":"62","author":"Leung","year":"2015","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jcf.2021.07.018_bib0016","first-page":"2561","article-title":"Accuracy of Transient Elastography Data Combined With APRI in Detection and Staging of Liver Disease in Pediatric Patients With Cystic Fibrosis","volume":"17","author":"Lewindon","year":"2019","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.jcf.2021.07.018_bib0017","first-page":"1207","article-title":"Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis","volume":"14","author":"Stonebraker","year":"2016","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.jcf.2021.07.018_bib0018","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/hep.29542","article-title":"New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, \u03b3-glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage","volume":"68","author":"Bussler","year":"2018","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jcf.2021.07.018_bib0019","doi-asserted-by":"crossref","DOI":"10.3791\/56084","article-title":"Optimized LC-MS\/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients","author":"Schneider","year":"2017","journal-title":"J Vis Exp JoVE"},{"key":"10.1016\/j.jcf.2021.07.018_bib0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2016.10.026","article-title":"Development of HPLC and LC-MS\/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO","volume":"1038","author":"Schneider","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jcf.2021.07.018_bib0021","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acsptsci.0c00103","article-title":"Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method","volume":"3","author":"Reyes-Ortega","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jcf.2021.07.018_bib0022","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2214\/ajr.171.6.9843315","article-title":"Normal liver, spleen, and kidney dimensions in neonates, infants, and children: evaluation with sonography","volume":"171","author":"Konu\u015f","year":"1998","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jcf.2021.07.018_bib0023","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1148\/radiol.2311020963","article-title":"Spleen length in childhood with US: normal values based on age, sex, and somatometric parameters","volume":"231","author":"Megremis","year":"2004","journal-title":"Radiology"},{"key":"10.1016\/j.jcf.2021.07.018_bib0024","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1148\/radiol.2017162931","article-title":"MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis","volume":"286","author":"Runge","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.jcf.2021.07.018_bib0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/MPG.0000000000001676","article-title":"Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives","volume":"65","author":"Debray","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2021.07.018_bib0026","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/gastro\/gox012","article-title":"Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy","volume":"5","author":"Procopet","year":"2017","journal-title":"Gastroenterol Rep"},{"key":"10.1016\/j.jcf.2021.07.018_bib0027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2021.07.018_bib0028","first-page":"111","article-title":"Orkambi in patients with cystic fibrosis and severe liver disease (Abstract TP92)","volume":"25","author":"Lim","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.jcf.2021.07.018_bib0029","first-page":"A144","article-title":"GP274 Liver tests in F508del homozygous cystic fibrosis patients on orkambi","volume":"104","author":"Paluck","year":"2019","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2021.07.018_bib0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jcf.2021.07.018_bib0031","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jcf.2021.07.018_bib0032","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/hep.28817","article-title":"The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity","volume":"64","author":"Fiorotto","year":"2016","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.jcf.2021.07.018_bib0033","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/hep4.1266","article-title":"Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice","volume":"2","author":"Debray","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jcf.2021.07.018_bib0034","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0000000000002864","article-title":"Reduced Intestinal Inflammation with Lumacaftor\/Ivacaftor in Adolescents with Cystic Fibrosis","author":"T\u00e9tard","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2021.07.018_bib0035","first-page":"2134","article-title":"Obliterative Portal Venopathy Without Cirrhosis Is Prevalent in Pediatric Cystic Fibrosis Liver Disease With Portal Hypertension","volume":"17","author":"Wu","year":"2019","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321013370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199321013370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:45:34Z","timestamp":1761601534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199321013370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1569199321013370"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2021.07.018","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2021.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}